4D Molecular Therapeutics, Inc.
FDMTNASDAQHealthcare● Active
$8.62
$-0.02(-0.23%)
Market Cap$450621309
P/E Ratio—
52W High$12.34
52W Low$3.68
4D Molecular Therapeutics, Inc. (FDMT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FDMT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $85.21M | $0.04M | $20.72M | $3.13M | $18.04M |
| Cost of Revenue | $7.63M | $0.00M | $97.10M | $80.25M | $61.36M |
| Gross Profit | $77.58M | $0.04M | ($76.37M) | ($77.12M) | ($43.32M) |
| Gross Margin %(computed) | 91.05% | 100.00% | -368.54% | — | -240.17% |
| Operating Expenses | |||||
| R&D Expenses | $195.70M | $141.30M | $97.10M | $80.25M | $61.36M |
| G&A Expenses | $49.06M | $46.58M | $36.49M | $32.91M | $28.01M |
| Total Operating Expenses | $237.13M | $187.88M | $36.49M | $32.91M | $28.01M |
| Operating Income | ($159.55M) | ($187.84M) | ($112.87M) | ($110.03M) | ($71.33M) |
| Operating Margin %(computed) | -187.24% | — | -544.65% | — | -395.46% |
| Interest Income | $19.48M | $27.05M | $12.21M | $2.57M | $0.14M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($140.11M) | ($160.87M) | ($100.84M) | ($107.49M) | ($71.32M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($140.11M) | ($160.87M) | ($100.84M) | ($107.49M) | ($71.32M) |
| Net Margin %(computed) | -164.43% | — | -486.59% | — | -395.37% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.42 | $-2.98 | $-2.58 | $-3.12 | $-2.46 |
| Wtd Avg Shares | 57.93M | 53.94M | 39.13M | 32.35M | 27.73M |
| EBITDA | ($151.92M) | ($181.14M) | ($108.66M) | ($107.63M) | ($69.81M) |
| EBITDA Margin %(computed) | -178.29% | — | -524.36% | — | -387.02% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more 4D Molecular Therapeutics, Inc. data
About 4D Molecular Therapeutics, Inc. (FDMT) Income Statement
4D Molecular Therapeutics, Inc. (FDMT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, FDMT reported revenue of $0.09B, gross profit of $0.08B (gross margin 91.05%), and net income of ($0.14B) — a net profit margin of -164.43%.
Frequently asked questions
FDMT · 4 questions4D Molecular Therapeutics, Inc. (FDMT) reported revenue of $0.09B for 2025, up 230194.6% year-over-year.
FDMT revenueFDMT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08